Royce & Associates LP Sells 14,000 Shares of Cryoport, Inc. (NASDAQ:CYRX)

Posted by Defense World Staff on Aug 6th, 2023

Royce & Associates LP decreased its position in Cryoport, Inc. (NASDAQ:CYRX – Free Report) by 29.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 34,198 shares of the consumer goods maker’s stock after selling 14,000 shares during the quarter. Royce & Associates LP owned approximately 0.07% of Cryoport worth $821,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in CYRX. State of Wyoming raised its holdings in Cryoport by 42.7% in the fourth quarter. State of Wyoming now owns 3,026 shares of the consumer goods maker’s stock worth $53,000 after purchasing an additional 905 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in Cryoport by 54.7% in the first quarter. Allspring Global Investments Holdings LLC now owns 2,484 shares of the consumer goods maker’s stock worth $60,000 after purchasing an additional 878 shares in the last quarter. Captrust Financial Advisors raised its holdings in Cryoport by 308.3% in the second quarter. Captrust Financial Advisors now owns 2,319 shares of the consumer goods maker’s stock worth $72,000 after purchasing an additional 1,751 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in Cryoport by 276.2% in the third quarter. Tower Research Capital LLC TRC now owns 3,961 shares of the consumer goods maker’s stock worth $96,000 after purchasing an additional 2,908 shares in the last quarter. Finally, Amundi bought a new position in Cryoport in the fourth quarter worth $99,000. Institutional investors own 97.46% of the company’s stock.

Cryoport Trading Up 0.4 %

Cryoport stock opened at $14.21 on Friday. The company has a debt-to-equity ratio of 0.76, a current ratio of 14.54 and a quick ratio of 13.90. Cryoport, Inc. has a one year low of $13.83 and a one year high of $45.36. The stock has a market capitalization of $647.12 million, a PE ratio of -18.22 and a beta of 1.23. The business’s fifty day moving average is $18.00 and its 200 day moving average is $20.34.

Cryoport (NASDAQ:CYRX – Get Free Report) last released its quarterly earnings data on Thursday, May 4th. The consumer goods maker reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.02. Cryoport had a negative return on equity of 4.90% and a negative net margin of 11.91%. The company had revenue of $62.82 million for the quarter, compared to analysts’ expectations of $62.15 million. During the same period last year, the firm posted ($0.31) earnings per share. Cryoport’s revenue was up 20.1% compared to the same quarter last year. On average, sell-side analysts predict that Cryoport, Inc. will post -0.9 EPS for the current year.

Insider Buying and Selling at Cryoport

In other Cryoport news, CFO Robert Stefanovich sold 19,918 shares of the stock in a transaction dated Wednesday, May 10th. The stock was sold at an average price of $21.94, for a total value of $437,000.92. Following the transaction, the chief financial officer now owns 107,150 shares of the company’s stock, valued at $2,350,871. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Cryoport news, Director Richard J. Berman sold 7,203 shares of the stock in a transaction dated Thursday, May 11th. The stock was sold at an average price of $21.51, for a total value of $154,936.53. Following the transaction, the director now owns 100,000 shares of the company’s stock, valued at $2,151,000. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Robert Stefanovich sold 19,918 shares of the stock in a transaction dated Wednesday, May 10th. The shares were sold at an average price of $21.94, for a total value of $437,000.92. Following the completion of the transaction, the chief financial officer now directly owns 107,150 shares in the company, valued at approximately $2,350,871. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 168,280 shares of company stock valued at $3,645,207. 10.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Stephens cut Cryoport from an “overweight” rating to an “equal weight” rating in a research note on Monday, July 17th. SVB Leerink cut Cryoport from an “outperform” rating to a “market perform” rating in a research note on Thursday, July 13th. BTIG Research cut their target price on Cryoport from $40.00 to $33.00 in a research note on Monday, July 17th. SVB Securities cut Cryoport from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $30.00 to $10.00 in a research note on Thursday, July 13th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $30.00 target price on shares of Cryoport in a research note on Friday, April 21st. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, Cryoport presently has a consensus rating of “Hold” and a consensus target price of $24.29.

Cryoport Company Profile

(Free Report)

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments: Global Logistics Solutions and Global Bioservices. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.